Byrne CD - Search Results

1

Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.

Nobili V, Alisi A, Musso G, Scorletti E, Calder PC, Byrne CD. Nobili V, et al. Among authors: byrne cd. Crit Rev Clin Lab Sci. 2016;53(2):106-20. doi: 10.3109/10408363.2015.1092106. Epub 2015 Oct 14. Crit Rev Clin Lab Sci. 2016. PMID: 26463349 Review.

2

Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD).

Ahmed MH, Byrne CD. Ahmed MH, et al. Among authors: byrne cd. Drug Discov Today. 2007 Sep;12(17-18):740-7. doi: 10.1016/j.drudis.2007.07.009. Epub 2007 Aug 27. Drug Discov Today. 2007. PMID: 17826687 Review.

3

Current treatment of non-alcoholic fatty liver disease.

Ahmed MH, Byrne CD. Ahmed MH, et al. Among authors: byrne cd. Diabetes Obes Metab. 2009 Mar;11(3):188-95. doi: 10.1111/j.1463-1326.2008.00926.x. Epub 2008 Jun 16. Diabetes Obes Metab. 2009. PMID: 18564173 Review.

4

Metabolic disturbances in non-alcoholic fatty liver disease.

Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Byrne CD, et al. Clin Sci (Lond). 2009 Apr;116(7):539-64. doi: 10.1042/CS20080253. Clin Sci (Lond). 2009. PMID: 19243311 Review.

5

Fatty liver: role of inflammation and fatty acid nutrition.

Byrne CD. Byrne CD. Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):265-71. doi: 10.1016/j.plefa.2010.02.012. Epub 2010 Mar 2. Prostaglandins Leukot Essent Fatty Acids. 2010. PMID: 20189787 Review.

6

Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities?

Ahmed MH, Abu EO, Byrne CD. Ahmed MH, et al. Among authors: byrne cd. Prim Care Diabetes. 2010 Oct;4(3):129-37. doi: 10.1016/j.pcd.2010.02.004. Epub 2010 Mar 17. Prim Care Diabetes. 2010. PMID: 20299294 Review.

7

Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?

Ahmed MH, Byrne CD. Ahmed MH, et al. Among authors: byrne cd. Drug Discov Today. 2010 Aug;15(15-16):590-5. doi: 10.1016/j.drudis.2010.06.007. Epub 2010 Jun 18. Drug Discov Today. 2010. PMID: 20601094

8

Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments.

Scorletti E, Calder PC, Byrne CD. Scorletti E, et al. Among authors: byrne cd. Endocrine. 2011 Dec;40(3):332-43. doi: 10.1007/s12020-011-9530-x. Epub 2011 Sep 6. Endocrine. 2011. PMID: 21894514 Review.

9

Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?

Bhatia LS, Curzen NP, Calder PC, Byrne CD. Bhatia LS, et al. Among authors: byrne cd. Eur Heart J. 2012 May;33(10):1190-200. doi: 10.1093/eurheartj/ehr453. Epub 2012 Mar 8. Eur Heart J. 2012. PMID: 22408036 Review.

10

Nonalcoholic fatty liver disease and vascular risk.

Bhatia LS, Curzen NP, Byrne CD. Bhatia LS, et al. Among authors: byrne cd. Curr Opin Cardiol. 2012 Jul;27(4):420-8. doi: 10.1097/HCO.0b013e328354829c. Curr Opin Cardiol. 2012. PMID: 22596186 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

518 results

Search Page

Filters